NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

Today’s positive decision follows the manufacturer, Daiichi Sankyo, offering a fair price for the treatment that the National Institute for Health and Care Excellence (NICE) determined to be ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

As a result, commercial teams are evolving as valuable partners to HCPs. From educating key experts before launch and ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...

No longer a far-off futuristic idea, artificial intelligence technology has seen its popularity skyrocket in recent years. | ...

The NHS England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML).